Swiss pharmaceutical giant Novartis AG has entered into an agreement to sell its 70.68% stake in Novartis India to leading Indian private equity firm ChrysCapital, according to a stock exchange disclosure from Feb. 20, 2026. This transaction marks ChrysCapital’s first majority acquisition in the Indian pharma sector, signaling the firm’s growing focus on healthcare investments and strategic expansion in India.
Earlier on February 19, financial news outlet Moneycontrol reported that ChrysCapital was in the final stages of negotiations to acquire the majority stake in Novartis India.
Deal Structure and Open Offer
Under the terms of the share purchase agreement, ChrysCapital and related entities are required to make a mandatory open offer to eligible public shareholders under SEBI regulations. The open offer price has been fixed at ₹860.64 per share, and the transaction is being managed by Axis Capital, the investment bank overseeing the acquisition.
The acquisition structure is as follows:
- Acquirer 1: 56.45% of equity at ₹860.64 per share
- Acquirer 2: 10.32% of equity at ₹701.25 per share
- Acquirer 3: 3.91% of equity at ₹701.25 per share
Once completed, ChrysCapital will have the right to nominate certain individuals to Novartis India’s board of directors. The company may also undergo a name change, subject to regulatory approvals.
At the close of trading on February 19, Novartis India shares stood at ₹830.45, giving the company a market capitalization of ₹2,050.45 crore.
ChrysCapital’s Pharma Strategy
ChrysCapital, a leading Indian private equity firm, has built a strong presence in the pharmaceutical and healthcare sectors, with current investments in Intas Pharma, Eris Lifesciences, Corona Remedies, and La Renon.
Industry experts say this deal demonstrates ChrysCapital’s confidence in the growth potential of India’s domestic pharmaceutical market, particularly for companies with established brands, robust product portfolios, and growth-ready infrastructure. Analysts expect ChrysCapital’s operational expertise and strategic guidance to accelerate market penetration, innovation, and product expansion in Novartis India.
This deal also marks a broader trend of private equity investment in Indian pharma, as investors look for long-term growth opportunities in the fast-growing domestic healthcare market.
Novartis India: A Market Overview
Novartis India has a wide-ranging portfolio catering to diabetes, chronic neurological, cardiological, and dermatological disorders, with its painkiller Voveran among the most recognized brands.
For the fiscal year 2024–25, Novartis India posted:
- Revenue: ₹356.27 crore
- Net Profit: ₹100.90 crore
The firm has consistently invested in research, development, and local manufacturing, helping it maintain a strong competitive edge in chronic care and specialty segments. With ChrysCapital at the helm, the company is expected to pursue strategic expansions, increased R&D initiatives, and possibly new product launches.
Strategic Rationale and Market Implications
The sale allows Novartis AG to streamline its global portfolio, focus on core high-growth segments, and unlock capital for reinvestment in research, innovation, and emerging markets.
For ChrysCapital, this acquisition provides a significant platform to consolidate its pharma holdings in India. Analysts expect:
- Accelerated growth in domestic and regional markets
- Expansion of treatment offerings and therapeutic areas
- Strategic partnerships with hospitals, distributors, and healthcare providers
Financial markets are likely to monitor the performance of Novartis India closely as ChrysCapital assumes control, particularly in the context of India’s growing demand for chronic and specialty medications.
Regulatory and Industry Perspective
The transaction requires SEBI approval for the mandatory open offer to public shareholders, ensuring transparency and compliance with Indian securities laws. The deal is also a bellwether for private equity activity in Indian healthcare, reflecting investor confidence in both the financial and operational resilience of domestic pharmaceutical companies.
Industry observers suggest that ChrysCapital may leverage its expertise to enhance operational efficiencies, optimize manufacturing capabilities, and drive long-term value creation for shareholders. This deal may also encourage other global pharma companies to consider strategic divestments in India, opening opportunities for domestic investors and PE firms.
Leave a Reply